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Animal modelsThe pathophysiological changes associated with Alzheimer's Disease (AD) begin decades before the emer-
gence of clinical symptoms. Understanding the early mechanisms associated with AD pathology is, therefore,
especially important for identifying disease-modifying therapeutic targets. While the majority of AD clinical
trials to date have focused on anti-amyloid-beta (Aβ) treatments, other therapeutic approaches may be nec-
essary. The ability to monitor changes in cellular networks that include both Aβ and non-Aβ pathways is es-
sential to advance our understanding of the etiopathogenesis of AD and subsequent development of cognitive
symptoms and dementia. Metabolomics is a powerful tool that detects perturbations in the metabolome, a
pool of metabolites that reﬂects changes downstream of genomic, transcriptomic and proteomic ﬂuctuations,
and represents an accurate biochemical proﬁle of the organism in health and disease. The application of
metabolomics could help to identify biomarkers for early AD diagnosis, to discover novel therapeutic targets,
and to monitor therapeutic response and disease progression. Moreover, given the considerable parallel be-
tween mouse and human metabolism, the use of metabolomics provides ready translation of animal research
into human studies for accelerated drug design. In this review, we will summarize current progress in the ap-
plication of metabolomics in both animal models and in humans to further understanding of the mechanisms
involved in AD pathogenesis. This article is part of a Special Issue entitled: Misfolded Proteins, Mitochondrial
Dysfunction, and Neurodegenerative Diseases.
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Alzheimer's Disease (AD) currently affects more than 5 million
Americans, with numbers expected to grow dramatically as the popula-
tion ages [1]. AD is a devastating neurodegenerative disorder charac-
terized by progressive memory loss and impairment in behavior,
language, and visuospatial skills [2]. Deﬁnitive diagnosis of AD re-
quires post-mortem examination of the brain, and is based on the
presence of Aβ plaques and neuroﬁbrillary tangles, the intracellular ﬁ-
brillar aggregates of the microtubule-associated protein tau that ex-
hibits hyperphosphorylation (p-tau) and oxidative modiﬁcations [3].
As evidenced by the many failed clinical trials for AD to date, with the
majority focusing on Aβ, there appears to be no treatment beneﬁt in the
fully symptomatic stage of the disease. One explanation for this lack of
efﬁcacy is that treatmentmay be administered too late in the disease pro-
cess. Indeed, AD pathophysiology is thought to begin several years, prob-
ably decades, before the emergence of clinical symptoms [4–10]. Amyloid
pathology associated with decreased levels of Aβ in cerebrospinal ﬂuid
(CSF) and increased accumulation in the brain is thought to precede
neuronal injury by up to 20 years. Moreover, neuronal injury and
neurodegeneration also precede cognitive decline, but are temporally
closer [4]. Thus, there is a critical need to identify the early pathological
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well as to the emergence of cognitive symptoms and dementia.
While Aβ is essential for a diagnosis of AD (including preclinical
AD for research purposes based on the National Institute of Aging–
the Alzheimer's Association (NIAAA) criteria), it is not sufﬁcient to ul-
timately cause cognitive impairment and dementia. Approximately
30% of individuals aged 70 and older do not develop cognitive impair-
ment or dementia despite having signiﬁcant amyloid load detected
with magnetic resonance imaging (MRI) [11,12]. Therefore, in order
to better understand the etiopathogenesis of AD, it is necessary to
focus on both Aβ and non-Aβ pathways to advance our understanding
of early disease mechanisms and to develop efﬁcient therapeutic ap-
proaches. Previous studies have suggested that non-Aβ mechanisms
including calcium dysregulation, mitochondrial dysfunction, altered
cell signaling, oxidative stress, inﬂammation, and lipid homeostasis
are perturbed inAD [13,14]. However, the temporal relationship between
thesemechanisms, ADpathology (i.e., Aβplaques, neuroﬁbrillary tangles,
and neurodegeneration), and clinical symptoms is not clear. Novel ap-
proaches are needed to monitor global changes in multiple biochemical
in order to reveal molecular mechanisms and associated biomarkers
that can lead to the development of new therapeutic strategies and
early diagnosis in the preclinical and early clinical (i.e., mild cognitive
impairment (MCI)) stages of AD, when treatment is likely to be most
effective.
Metabolomics allows monitoring the perturbations in a pool of
metabolites that reﬂects changes downstreamof genomic, transcriptomic
and proteomic ﬂuctuations. Metabolomics represents an accurate bio-
chemical proﬁle of an organism inhealth anddisease aiding to further un-
derstanding of alterations in complex biological networks involved in AD
[15,16]. The strength of metabolomics is in its ability to identify dynamic
qualitative and quantitative changes in a large number of individual me-
tabolites representing multiple functional networks and pathways. An
inherent advantage of metabolomics, compared to the use of proteomics
or genomics, is the ability to directly translate data across species, espe-
cially with regards to drug development. Since metabolic pathways are
conserved through evolution, and are essentially similar in rodents and
humans, the metabolic signatures identiﬁed in mechanistic and thera-
peutic studies of AD animal models could be directly translated intoTable 1
Analytical platforms utilized in metabolomic research in animal models of AD and AD patie
Analytical platforms Advantages
Nuclear magnetic resonance
(NMR) spectroscopy
• universal detection
• excellent quantitative precision
• high throughput (N100 samples/day
• rigorous structural analysis of many
cell suspensions, intact tissues, or wh
• structural determinations including th
labels (e.g., 13C, 15N, or 2H) generate
• speed
• detection of unidentiﬁed metabolites
Mass spectroscopy (MS) • most important technique for known
• high sensitivity for low abundance s
• detection of molecules that are not y
Gas chromatography–mass spectroscopy
(GC–MS)
• structural information
• quantitative precision
• high throughput
• higher sensitivity compared to NMR
• excellent tool for targeted studies
Liquid chromatography-mass spectroscopy
(LC-MS)
• measures metabolites without deriva
• could be tailored for speciﬁc class of
• detection of broad range of compoun
• stable isotope/ﬂux experiments
• excellent tool for broad non-targeted
• detection of unidentiﬁed metabolites
immediately known
Liquid chromatography–electrochemistry array
(LCECA)
• small molecule detection based on o
• high reproducibility
• high sensitivityhuman studies. Moreover, metabolomic proﬁling is inexpensive, time-
efﬁcient, and can be done in a variety of easily accessible sources such
as CSF, plasma and peripheral tissue, thus highlighting the clinical utility
of this approach. Here, we will review current data generated using
metabolomics in animal models of AD and in clinical studies.
2. Metabolomic platforms
The size of the metabolome has not been deﬁned and could range
from a few thousand to tens of thousands of metabolites [17,18]. The
ability to simultaneously measure dynamic changes in many mole-
cules in biological samples became available only recently through
the utilization of such advanced analytical technologies as high resolution
nuclearmagnetic resonance (NMR) andmass spectroscopy (MS) coupled
with either high or ultrahigh resolution liquid (LC) or gas (GC) chroma-
tography, and the development of sophisticatedmethods of data analysis.
An excellent, detailed description of the analytical platforms available for
multiple metabolomic applications has been published previously [19].
We will brieﬂy describe the metabolomic platforms utilized to date in
AD research (Table 1).
A number of early metabolomic studies employed 1H NMR, also
called Magnetic Resonance Spectroscopy (MRS), to determine changes
associated with disease progression in AD animal models and AD pa-
tients [16]. An advantage of 1H MRS is the rapid detection of a large
number of molecules, with excellent quantitative precision, in a high
throughput manner (Table 1). This method is also non-invasive and
provides an in vivo opportunity to studymetabolites in living organisms
[16]. However, a disadvantage of 1HMRS is in its high cost and relatively
low sensitivity.
MS is the most utilized technique for the identiﬁcation and quantiﬁ-
cation of known metabolites, both for the detection of molecules with
low abundance signals (e.g., hormones) and also for the detection of re-
producible, but unidentiﬁed, molecules. The coupling of MS with either
gas chromatography (GC) or liquid chromatography (LC) has been
successfully applied for targeted metabolomics to analyze changes
in lipids (lipidomics) or other metabolites (e.g., catecholamines).
These methods are also used to detect global changes in biochemical
networks (non-targetedmetabolomics). Compared toNMR,MS ismorents.
Disadvantages
)
metabolites in crude extracts,
ole organisms
e atomic positions of isotopic
d during stable isotope tracer studies
• relatively poor sensitivity
• high initial cost of NMR; instruments
(over one million dollars)
metabolite identiﬁcation
ignals
et identiﬁed
• inability to study molecules that cannot be
readily volatilized
• low mass accuracy
• increased mass accuracy is associated with
higher initial cost and reduced throughput.
tization
compounds
ds;
studies
with the exact mass
• lack of consistent quantitative precision
xidation/reduction • lack of structural information
• low throughput
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(Table 1). However, one of the disadvantages of MS is that it typically
requires chemical manipulation in order to produce ionic species that
are more readily separated.
LC-electrochemistry array metabolomics platform (LCECA) is an-
other method utilized for both targeted and non-targeted applica-
tions to detect changes in neurotransmitter pathways and pathways
involved in oxidative stress [20,21]. This method has high sensitivity
and reproducibility. However, it does not allow generation of struc-
tural information and has relatively low throughput (Table 1).
3. Metabolomics in animal models of AD
The familial form of AD (FAD), which has an early-onset (b65 years
of age), is caused by mutations in the genes encoding amyloid precursor
protein (APP) and presenilins 1 and 2 (PS1 and PS2) [22]. There is a num-
ber of well-characterized transgenic animal models of FAD that closely
recapitulate the onset and progression of human disease. These models
offer an outstanding opportunity to investigate the early pathologic
disease mechanisms in order to identify novel therapeutic targets and
relevant biomarkers. Further, the utilization of FAD animals allows
establishing the direct correlations between metabolomic signatures in
affected brain regions, plasma or peripheral tissue and the extent of
disease progression including levels of amyloid deposition and cognitive
decline, which cannot be accomplished in humans.
Neurochemical proﬁles in the brain of living FAD mice were de-
ﬁned using 1H MRS-based metabolomics (Table 2) [23–26]. Despite
the fact that animal models in these studies differed in the origin of
FAD mutations, age, and examined brain regions, all studies reported
a decrease in the levels of N-acetylaspartate (NAA) and glutamate
(Table 2). NAA is synthesized under normal conditions in the mito-
chondria of neurons, and is considered a marker of neuronal density
and integrity [27]. However, the details of its biological function in the
brain are not well understood, and there is evidence that NAA could be
involved in lipid synthesis intomyelin, in osmoregulation, in bioenerget-
ics of neuronal mitochondria, and axon-glial signaling [28]. It is interest-
ing to note that changes in NAA and glutamate were identiﬁed in theTable 2
Summary of metabolomic studies conducted in animal models of AD.
Animal model Age Examined tissue
APP
(Tg 2576, K670N/M671L)
19 months Cerebral cortex (in
and in vitro)
APP/PS1
(APP K670N/M671L + PS1 M146L)
2.5–30 months Cortex and hippoca
PS2APP
(PS2 N141I + APP K670N/M671L)
4–24 months Frontal cortex
TgCRND8
(APP KM670/671NL + V717F)
2–3 months
12–13 months
Cortex, frontal cort
cerebellum, hippoc
olfactory bulb, pon
midbrain and striat
APP/PS1
(APP K670N/M671L + PS1 M146L)
16 weeks Hippocampus
APP
(Tg 2576, K670N/M671L)
36 weeks Hippocampus
PS1
(M146L)
36 weeks Hippocampus
APP/PS1
(APP K670N/M671L + PS1 M146L)
12–20 weeks old
animals treated with
Donepezil
Striatum
cortex
Hippocampusbrain of adult APP and PS2APP mice examined at 19 and 20 months of
age, respectively, when the amyloid toxicity was wide spread (Table 2)
[23–26], as well as in the brain of young APP/PS1 animals of 2.5 months
of age, prior to the development of neurological andmemory phenotype
and amyloid deposits (Table 2) [24,29]. In addition to the reduction in
NAA and glutamate levels, APP/PS1 mice showed a signiﬁcant increase
in myo-inositol (m-In), which correlated with age and severity of AD in
these animals (Table 2) [24]. Since m-In is expressed to the greater ex-
tent in glial cells compared to neurons, its levels are considered to repre-
sent the extent of gliosis [30,31]. Similar to the results in FAD animals,
levels of NAA, m-In and glutamate were found to ﬂuctuate in the similar
way with progression of AD in humans suggesting that FAD animals ac-
curately recapitulate metabolic changes associated with human disease
[32,33]. Moreover, along with the decreased levels of NAA indicative of
mitochondrial dysfunction, metabolic proﬁles in the brains of PS2APP
mice also showed progressive age-dependent development of brain
hypometabolism [25]. This data is consistent with the decrease in brain
metabolism observed in human carriers of the ApoE4mutation that pre-
disposes to late-onset AD [34–36]. Furthermore, these spectroscopic
measures in PS2APP mice in vivo correlated well with the progressive
formation of Aβ plaques in the frontal cortex. A diagnostic test, based
on the changes in NAA and glutamate levels in PS2APP mice, reached
92% sensitivity and 82% speciﬁcity at age 20 months [25], demonstrating
the robustness of the metabolomic approach in disease diagnosis.
Additional study conducted in TgCRND8 mouse model using 1H
NMR examined metabolic changes in the extracts from eight brain
regions including cortex, frontal cortex, cerebellum, hippocampus, ol-
factory bulb, pons, midbrain and striatum (Table 2) [26]. This study,
similar to the experiments conducted by Marjanska and colleagues
[24], assessed metabolic changes in relationship to disease progres-
sion starting with animals 2–3 months of age and continuing with
mice 12–13 months old. Analysis of the NMR spectra discriminated
control from TgCRND8 tissues in most of the examined brain regions,
with hippocampus and cortex being affected to a greater extent. In a
good agreement with the data reported for other FAD animals (Table 2,
1H MRS), the authors found a decrease in NAA, glutamate, glutamine,
taurine, gamma-amino butyric acid (GABA), choline, phosphocholine,Analytical
platform
Changes in most important metabolites References
vivo MRS Increase: taurine
Decrease: NAA, glutamate, glutathione
[23]
mpus 1H MRS Increase: myo-inositol
Decrease: NAA and glutamate
[24]
1H MRS Decrease: NAA and glutamate were signiﬁcantly
reduced in the older animals
No changes in myo-inositol
[25]
ex,
ampus,
s,
um
1H NMR Increase: free fatty acids, leu-ile/val, lactate,
Leu/lys/Arg, alanine, glycine, aspartate, serine
Decrease: GABA, NAA, glutamate, glutamine,
creatine/P-creatine, taurine, NAAG,
myo-inositol, choline/P-choline, succinate,
malonate
[26]
GC/MS Increase: threonic acid, ethanolamine, alanine,
mannitol, glycerol 3-P, pyroglutamic acid, NAA,
creatinine, lactic acid, succinic acid,
methylglutamate, NAD, adenosine, adenine,
citric acid
[37]
GC/MS Increase: adenosine, AMP, Adenine,
Decrease: NAA, Myo-inositol, pantothenic acid,
Pi, threose, creatinine, malonic acid, ATP,
Glycerol, Inosine, Citric acid, ADP
[37]
GC/MS Decrease: ADP, ATP, NAD, Pi, fumaric acid,
myo-inositol, malonic acid, lysine, GDP, threose,
glycerol, GTP, NAA, glutamic acid, GMP
[37]
1H MRS Increase: glutamate/creatine ratio choline/
creatine ratio
Decrease: taurine/creatine ratio
[38]
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cortex, frontal cortex and midbrain of TgCRND8 animals. Metabolites
that discriminated between old and youngmouse tissuewere lactate, al-
anine, lysine andN-acetyl-aspartyl-glutamate,which decreasedwith age
and glutamine, Cre, m-In, and malonate, which increased as mice aged.
The authors also reported an increase in lactate, aspartate, glycine and
other amino acids including alanine, leucine, iso-leucine, valine and
water-soluble free fatty acids. It is interesting to note that no sex differ-
ences were observed in metabolomic proﬁles in TgCRND8mice. Overall,
this study, for the ﬁrst time, demonstrated that the perturbations in
metabolism caused by expression of FAD mutations are widespread
and include the cerebellum and midbrain. Furthermore, disease-related
changes were associated with a wide range of metabolites providing a
justiﬁcation for metabolomics as a valuable tool for diagnosis and moni-
toring the AD progression [26]. Taken together, studies using 1HMRS an-
alytical platform conﬁrmed that metabolic changes correlate with AD
progression in multiple animal models of AD, and these changes resem-
ble alterations observed in human AD patients. However, the major
limitation of these animal studies was a relatively limited number ofme-
tabolites detected with 1H MRS.
Using GC/MS-based metabolomic approach we have investigated
metabolic changes in the brain of APP, PS1 and APP/PS1 FAD mice
prior to the development of amyloid plaques and cognitive deﬁcit
(Table 2) [37]. Analysis of metabolomic proﬁles in the hippocampal
tissue using partial least squares discriminant analysis (PLS-DA) revealed
that PS1, APP and APP/PS1 mice have metabolomic signatures that were
distinct fromnon-transgenic (NTG) littermates and also from each other.
Moreover, for the ﬁrst time in the animal metabolomic study, we
demonstrated that metabolic signatures in APP/PS1 mice had signiﬁcant
sex differences. Thus, NTG female and male mice had very similar
metabolomic proﬁles, while proﬁles of APP/PS1 femalemicewere affect-
ed to a greater extent than in male APP/PS1 animals [37]. Metabolites in
the separate pair comparison revealed presence of characteristic signa-
tures of mitochondrial toxicity with altered tissue levels of energy me-
tabolites ATP, ADP, AMP, nicotinamide adenine dinucleotide (NAD),
adenosine, fumaric acid, adenine, Cre and β-alanine. Increased levels of
adenosine, AMP and fumaric acid and decreased levels of NAA indicated
altered ability to maintain oxidative phosphorylation leading to mito-
chondrial stress and energetic dysfunction. Metabolic pathway analyses
revealed that in all three FADmousemodels therewere signiﬁcant alter-
ations in the levels ofmetabolites involved in energymetabolism includ-
ing nucleotide metabolism, mitochondrial Krebs cycle, energy transfer,
carbohydrate, neurotransmitter and amino acid metabolic pathways.
However, along with the pathways equally affected in all three FAD
mouse models, we identiﬁed metabolic pathways and metabolites that
were speciﬁc to the mutation. Thus, alteration in neurotransmitter me-
tabolism and energy transfer pathway was affected to a greater extent
in APP and PS1 animals. Synergistic effect of both mutations in APP/PS1
mice resulted in signiﬁcantly stronger alterations in glycolytic pathway
that involved Krebs cycle, and neurotransmitter and amino acid metab-
olism. Using a battery of biochemical and cell biology techniques, we
demonstrated that mitochondrial dynamics, distribution, and function,
including the integrity of synaptic mitochondria were affected in the
brain tissue from all three FAD animal models early in AD progression
[37]. Therefore, our data suggest that metabolomics accurately detects
early disease-related changes associatedwithmitochondrial dysfunction
in presymptomatic FAD animals justifying the application of this ap-
proach for diagnostic purposes.
In addition to the identiﬁcation of altered pathways and a panel of
affected metabolites associated with AD progression, metabolic signa-
tures could be used to monitor efﬁcacy of therapeutic intervention. The
effect of donepezil administration in APP/PS1 mice was monitored in
vivo using 1H MRS (Table 2) [38]. Donepezil is an acetylcholine-esterase
inhibitor, which enhances the life of the neurotransmitter acetylcholine
in the synapse and increases cholinergic neurotransmission [39,40]. The
FDA approved the use of donepezil for symptomatic treatment of ADpatients [41]. Indeed, application of metabolomics to analyze changes in
the brain metabolites in donepezil-treated APP/PS1mice revealed signif-
icant decrease in the ratio of taurine/Cre and increase in choline/Cre and
glutamate/Cre indicative of an improved cholinergic activity [38].
Taken together, data generated to date using multiple metabolomic
platforms suggest that animal models of AD closely mimic changes
in metabolic networks involved in disease progression in humans.
Metabolomics could distinguish age and sex-speciﬁc changes associ-
ated with early disease mechanisms and could be utilized to monitor
therapeutic efﬁcacy of experimental drugs. Taking into consideration
that biochemical pathways are essentially conserved between humans
and rodents, metabolomics could provide translational biomarkers for
accelerated dug development.
4. Metabolomic studies in AD patients
Multiple human studies have used metabolomics to establish
disease-related plasma or CSF metabolite differences between cogni-
tively normal (CN) individuals, mild cognitive impairment (MCI), and
AD patients as predictors of AD progression. However, direct compar-
ison of results is difﬁcult due to the utilization of diverse analytical
platforms, different sample mediums (CSF or plasma) collected either
from living individuals or post-mortem, and varied distributions in
age, disease severity and sex. Since a comprehensive overview of applica-
tion of theNMRspectroscopy-basedmetabolomics inAD is provided else-
where [16], we will focus on studies (grouped by the sample medium)
that have utilized MS and LCECA analytical platforms (Table 3).
4.1. Post-mortem ventricular CSF
Using LCECA, Kaddurah-Daouk and colleagues [42] examined
post-mortem ventricular CSF from 15 AD patients and 15 age- and
sex-matched CN individuals.While hundreds ofmetaboliteswere iden-
tiﬁed, the authors restricted their analyses to 33knownmoleculeswith-
in key neurotransmitter pathways (e.g., dopamine and serotonin) and
pathways involved in oxidative stress. Norephinephrine (NE) levels
were signiﬁcantly decreased in AD cases compared to controls. There
were also non-signiﬁcant trends for group differences in tyrosine, tryp-
tophan, purine, and tocopherol pathways. Notably, a model that includ-
ed tryptophan, NE, and indoleacetic acid provided complete separation
of the groups. A limitation of that study is that metabolite levels in ven-
tricular CSFmay be impacted by the death process and post-mortem in-
tervals. However, the authors also reported signiﬁcant correlations
between several metabolites and both plaque and tangle pathology,
providing further credence to the ﬁndings. Speciﬁcally, depletion of
NE, methionine, alpha-tocopherol, 3-methoxytyramine, and metabo-
lites within the purine pathway were associated with neuroﬁbrillary
tangle formation and/or Aβ deposition. In contrast, higher levels of
5-hydroxytryptophan were associated with greater neuroﬁbrillary tan-
gle and Aβ burden (Table 3).
4.2. In vivo CSF
Since each metabolomic platform has limitations (Table 1), the
utilization of multiple analytical platforms should help to obtain
more accurate metabolic signatures of disease process in bioﬂuids
and tissues [43]. Czech and colleagues [44] combined GC–MS and
LC-MS/MS for broad proﬁling and solid phase extraction-LC-MS/MS
(SPE-LC-MS/MS) to establish differences in catecholamines and ste-
roids in the CSF of 51 CN participants, 53 mild AD, and 26 moderate
AD patients (Table 3). Among the 343 detected metabolites, 80 com-
pounds were unambiguously identiﬁed and absolute quantiﬁcation was
determined. Notably, the number of metabolite differences between AD
and CN subjects wasmuch larger for women compared tomen, in agree-
ment with ﬁndings in FAD mice [37]. This observation highlights the
importance of sex-speciﬁc research using metabolomics, particularly in
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the mild AD group had signiﬁcantly more metabolic changes compared
to the moderate AD group. This might be expected as the accumulating
pathology with advanced AD leads to the loss of neurons and metabolic
function. The combination of increased cysteine and decreased uridine
levels best separated AD and CN groups, with approximately 75% sensi-
tivity and 75% speciﬁcity. Uridine is a nucleoside and one of the precur-
sors of phosphatidylcholine, a major component of cell membranes.
Thus, decreased uridine levels could be indicative of neurodegeneration.
The authors suggested that the observed increase in cysteine could reﬂect
an imbalance in the homocysteinemetabolism. Interestingly, levels of NE
were also increased in the CSF of AD patients, which is in contrast to the
ﬁndings reported by Kaddurah-Daouk et al. [42] supporting the notion
that the death process could have affected the metabolic proﬁles in that
study.
In addition to examining changes in metabolites for diagnostic
purposes, a recent study used capillary electrophoresis–mass spectrom-
etry (CE–MS) to identifymetabolic changes predictive of AD progression
(Table 3) [45]. Compared to other MS techniques, CE is particularly suit-
ed for the rapid separation of ionic and highly polar metabolites. Study
participantswere followed for 2 years and categorized into the following
groups based on their baseline diagnosis and progression: subjective
memory complaints that remained stable over the two-year follow-up
period (SCI-nonAD), MCI that remained stable (MCI-nonAD), MCI that
progressed to AD (MCI-AD), andAD. Sampleswere divided into a trainingTable 3
Summary of metabolomic studies conducted in AD patients.
Analytical platform Samples Findi
• LCECA
• Focused on neurotransmitter and
oxidative stress pathways
Post-mortem ventricular CSF from
15 AD and 15 CN
• No
• NE
wit
• 5-h
tan
• GC–MS and LC-MS/MS for broad
proﬁling
• SPE-LC-MS/MS for catecholamine
and steroids
CSF from 79 AD (53 mild and 26
moderate) and 51 CN
• Gre
• Gre
• Cor
• The
and
• CE–MS for non-targeted
metabolomics
Test set: CSF from 19 SCI, 22 stable
MCI, 9 MCI progressors, and 23 AD.
• Bas
85.
• For
cor
• Cho
diff
Validation set: 4 SCI, 2 stable MCI,
4 MCI progressors, 2 AD.
• UPLC-MS Plasma from 16 AD, 12 MCI, and 10 CN. • Hig
and
• GC
• UPLC-MS for global lipidomics
• 2D GC x GC-TOFMS for global
proﬁling of small polar
metabolites
Serum from 46 CN, 37 AD, 52 MCI who
progressed to AD, and 91 stable MCI.
• AD
inc
• Dih
not
• UPLC-ToF-MS Plasma and CSF from 15 CN, 15 MCI,
and 15 AD.
• The
dis
• In b
pat
bio
me
hor
• LC-MS
• Analyses focused on phospholipids
Plasma from 10 CN, 10 MCI, and 10 AD. • AD
• Lys
sev
• Liquid chromatography–atmospheric
pressure chemical ionization-mass
spectroscopy
• Analyses focused on sterol-related
compounds
Test set: Plasma and CSF from 10 AD
and 10 CN.
• Pla
• No
spe
• Dem
in s
Validation set: Plasma from 42 CN,
26 MCI, and 41 AD
• Non-targeted approach using
MDMS-SL
Plasma from 26 AD and 26 CN • Lon
to c
• Lev
• Rat
ADdataset consisting of 73 CSF samples across the diagnoses and a test set
consisting of 12 samples. Ten metabolites were identiﬁes that allowed
90.1% correct classiﬁcation for the four groups by linear discriminant
analysis (LDA). These metabolites included choline, valine, arginine,
suberylglycerine, carnitine, creatine, serine, and histidine. Using this
same LDAmodel, 83% of the 12 CSF test samples, initially blinded to di-
agnosis, were correctly classiﬁed. Itwill be important to conﬁrmwheth-
er these molecules can be used as predictors of disease progression in
larger cohorts. Future research is also needed to examine the relation
between changes in identiﬁedmetabolites and pathological features in-
cluding Aβ plaques and neuroﬁbrillary tangles.
4.3. Blood
While CSF metabolites are thought to be most reﬂective of brain
changes compared to blood, the collection of CSF is invasive and is not
ideal for screening purposes in the general population or for repeated
follow-up visits to assess the efﬁcacy ofmedications on disease progres-
sion. Therefore, the identiﬁcation of blood-based biomarkers would be
ideal for clinical use and, as a result, metabolomic studies have also
focused on proﬁling in blood. Using ultra-performance liquid chroma-
tography (UPLC) coupled with MS, Greenberg and colleagues [46]
examined metabolic changes in plasma in 10 CN elderly individuals,
12 MCI, and 16 AD patients (Table 3). Partial least squares discriminant
(PLSD) analysis demonstrated a clear separation of subject groups. Twongs References
repinephrine (NE) levels lower in AD vs. CN
, methionine, and alpha-tocopherol negatively correlated
h tangle formation and/or amyloid deposition
ydroxytryptophan and tyramine positively correlated with
gle formation and/or amyloid deposition
[42]
ater metabolic changes in female vs. male AD
ater metabolic changes in mild vs. moderate AD
tisol positively correlated with AD severity
combination of cysteine and uridine had 75% sensitivity
speciﬁcity for separating mild AD from CN
[44]
ed on LDA, correct classiﬁcation of training set for 94.7% of SCI,
7% of MCI-stable; 88.9% of MCI progressors; and 90.9% of AD
the test set, 83% of the samples were correctly assigned to their
responding group
line, valine, carnitine, serine, and a tripeptide signiﬁcantly
ered by group in targeted analyses
[45]
h-inﬂuence variables for AD included glycerophosphocholine
D-glucosamininde
A, GCDCA, and GDCA were increased in MCI and AD vs. CN
[46]
patients had decreased concentrations of several lipid classes,
luding phosphatidylcholine, plasmalogens, sphingomyelins, and sterols
ydroxybutanoic acid best separated MCI patients who did and did
progress to AD over 2 years
[52]
number of affected pathways in CSF and plasma increased with
ease severity
oth the CSF and plasma there were signiﬁcant group differences in
hways related to energy metabolism and mitochondrial function; lipid
synthesis, trafﬁcking and metabolism; amino acid biosynthesis and
tabolism; neurotransmitter biosynthesis and metabolism; and
mone biosynthesis and metabolism
[55]
and CN had complete group separation
ophospolipid 18:1 decreased incrementally with increasing disease
erity (CN N MCI N AD)
[59]
sma and CSF desmosterol was decreased in AD vs. controls
table sex differences in desmosterol levels and in the sensitivity/
ciﬁcity of group separations (e.g., MCI vs. AD and MCI vs. CN)
onstrated importance of methodology as there were no differences
terol levels when GC–MS was used
[60]
g-chain sphingomyelin species were lower in AD patients compared
ontrols
els of 2 ceramide species (N16:0 and N21:0) were higher in AD than CN
ios of ceramide to sphingomyelin species better discriminated between
cases and CN compared to either lipid species alone
[63]
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D-glucosaminide. While no relationship between the later metabolite
and AD mechanisms has previously been reported, research conducted
in both post-mortem CSF and CSF from living subjects demonstrated
that glycerosphophocholine levels were elevated in AD patients relative
to controls [47–49]. The replication of these ﬁndings in the blood sug-
gests this metabolite may indeed be indicative of changes in the brain
and could serve as a potential diagnostic marker for AD. Another inter-
esting result in this studywas the demonstration that levels of three bile
acids (glycocholate, glycodeoxycholate, and glycochenodeoxycholate)
were elevated in both MCI and AD patients relative to controls
(Table 3). While there is dearth of data examining the role of bile
acids in neurodegenerative diseases, recent studies have suggested
that bile acids are present in the brain [50] and that they may atten-
uate APP processing and Aβ deposition in APP/PS1 mice [51].
In another study, Oresic and colleagues [52] used UPLC-MS and 2D
GC–ToF-MS to determine predictors of conversion from MCI to AD
over a 2-year period (Table 3). The authors examined serum from
46 CN individuals, 91 who had stable MCI at baseline and follow-up,
52 MCI who progressed to dementia, and 37 AD cases. The main me-
tabolite that separated MCI cases that did and did not progress was
2,4-dihydroxybutanoic acid, which was higher in those that progressed
to AD. While little is known about this molecule in serum, it is
over-produced under conditions of low oxygen [53]. Thus, this marker
may represent hypoxic pathways involved in AD [54].
4.4. CSF and blood
As blood represents a non-invasive, inexpensive, and acceptable
source for repeated measures and CSF most closely reﬂects brain-
speciﬁc changes, the identiﬁcation of metabolomic differences in both
mediums within the same subjects would validate the use of speciﬁc
blood-based metabolites as diagnostic or prognostic biomarkers of AD.
We therefore examined metabolomic differences, using UPLC-ToF-MS,
in the CSF and plasma of 15 CN, 15 MCI, and 15 AD subjects [55]
(Table 3). There were distinct group differences in multiple metabo-
lites and pathways in both the plasma and CSF. Approximately 30% of
the metabolic pathways were altered in the CSF in MCI patients versus
CN, and 60% in AD patients versus CN, were also affected in the plasma
from the same individuals, showing the consistency betweenmediums.
The number of affected pathways in the CSF and plasma increased with
disease severity. For example, while only L-arginine and tryptophan
pathways were altered in both plasma and CSF of MCI patients, the
number of pathways equally affected in the CSF and plasma of AD
patients considerably increased and included beta-alanine, aspartate
and aspargine, alanine, L-cysteine, L-methionine, methionine–cysteine–
glutamate alongwith L-arginine and lysinemetabolic pathways. Further,
compared to CN, bile acid biosynthesis andmetabolismwas signiﬁcantly
affected in the plasma of AD patients, which is similar to the results of
Greenberg and colleagues [46]. Our data demonstrate that CSF and plas-
ma have signiﬁcant overlap in affected pathways, and most of the path-
ways affected early in MCI continue to be altered in AD subjects. In both
the CSF and plasma ofMCI and AD groups, the perturbed canonical path-
ways included those related to energy metabolism and mitochondrial
function; lipid biosynthesis, trafﬁcking and metabolism; amino acid bio-
synthesis and metabolism; neurotransmitter biosynthesis and metabo-
lism; and hormone biosynthesis and metabolism.
4.5. Lipidomics
Perturbations in lipid metabolism have been noted since Alois
Alzheimer's ﬁrst reported case of AD [56], but understanding of
their relationship and contribution to AD pathology has been hampered
by inadequate methodology. Lipidomics is a newer metabolomic ap-
proach that can be used to conduct system-level analyses of lipids in bi-
ological samples [57]. Lipids have several important roles in the CNSand periphery including the maintenance of membrane structure, the
formation of lipid rafts, and the involvement in signaling pathways. Sev-
eral lines of evidence suggest that the dysregulation of cholesterol,
sphingolipid, and fatty acid metabolism may initiate or accelerate AD
pathology and, therefore, be important in the etiopathogenesis of AD
and future therapeutic strategies [58].
While conventional metabolomic methods can identify some lipids
such as cholesterol and fatty acids, other lipids will not be identiﬁed be-
cause they have polarities that will partition them into the aqueous
phases during the extraction procedures and make them “invisible” for
detection. As a result, speciﬁc lipidomic methods have evolved to con-
duct both global (non-targeted) lipid analyses as well as targeted mea-
sures of speciﬁc lipid classes; both methodologies have been utilized in
AD research. Sato and colleagues [59] measured phospholipids and ste-
rols in plasma from 10 CN, 10 MCI, and 10 AD patients (Table 3). Using
PLS analyses and a supervised clustering method, the authors demon-
strated a complete separation between the AD and CN groups. Among
the MCI individuals, half had lipid proﬁles similar to the AD patients
and half similar to the CN. This might be expected, since MCI represents
a heterogeneous group that includes individuals who will progress to
AD, who will progress to other dementias, and individuals who will not
progress but remaining MCI. While determination of the speciﬁc lipids
that were unique to each group was ongoing, lysophospholipid 18:1
was found to have incremental decreases such that CN N MCI N AD.
Using similar methodology, Sato et al. extended their research to
examine group differences in plasma sterols [60] (Table 3). In an ini-
tial test sample of plasma from 10 AD cases and 10 CN, several peaks
were identiﬁed that differentiated the groups. Levels of desmosterol,
a precursor to cholesterol, were signiﬁcantly (p b 0.009) decreased
in AD patients versus CN. To validate this ﬁnding, the authors exam-
ined samples from 42 elderly CN, 26 MCI, and 41 AD patients and con-
ﬁrmed that levels of desmosterol were sequentially decreased with
disease severity (CN N MCI N AD). There were also negative correlation
between plasma desmosterol levels and theMini-Mental State Examina-
tion (MMSE),with the ﬁndings strongest among females. Two important
aspects of this study provoke further discussion. First is the speciﬁc iden-
tiﬁcation of desmosterol. It is well established that in late-life, within
10 years of dementia onset, lipid levels begin to decrease [61]. This is
likely due to changes in dietary habits, weight loss, and frailty. Thus,
changes in desmosterol levels couldmost closely represent thepatholog-
ical progression of AD. Second, a previous study using GC–MS suggested
there were no differences in desmosterol levels between control and AD
patients [62]. The authors therefore rerun their sampleswithGC–MSand
also found that levels of desmosterol did not differ [60]. This ﬁnding
highlights differences in methodologies and suggests that LC-MS
represents a more sensitive analytical platform capable of separating
desmosterol from metabolites with similar structures.
Another lipidomic study [63] utilized a non-targeted multi-
dimensional mass spectrometry-based shotgun lipidomic (MDMS-SL)
approach to measure levels of over 800 species of phospholipids, phos-
phatidylinositol, sphingomyelin, ceramide, triacylglycerol, cholesterol,
and cholesterol esters (Table 3). An advantage of the shotgun approach
is the speed, robustness, and the capacity for automation. However,
identiﬁcation of low abundance lipids and the complication with
strong ion suppression can be problematic. Using plasma from 26
AD (17 with mild and 9 with moderate AD) and 26 CN, it was found
that sphingolipid levels were signiﬁcantly lower, and ceramide levels
were higher in ADpatients compared to controls. The ratio of ceramides
to sphingomyelins for speciﬁc carbon chain lengths (e.g., C22:0) more
robustly discriminated between AD cases and CN compared to either
lipid type alone. Further, among AD cases, there were strong correla-
tions (p b 0.004) between the rank of the changed mass levels of
sphingomyelin and ceramides and the rank MMSE score. While this
study was the ﬁrst to examine a shotgun sphingolipidomic approach,
the ﬁndings are in line with previously published data generated
with targetedmethods where AD patients were found to have higher
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and CSF [66] compared to normal controls. Targeted studies of plasma
sphingolipids have also highlighted the importance of blood ceramides.
High blood ceramide levels predicted cognitive impairment and AD
among CN individuals [11,67]; memory decline and hippocampal vol-
ume loss among amnesticMCI patients [68]; and faster rates of cognitive
decline among AD patients [69]. Thus, the robustness of the ﬁndings
across methods and sample severities (brain tissue, CSF, plasma) sug-
gests that the sphingolipid pathway is perturbed in AD andwarrants ad-
ditional research relevant to identiﬁcation of potential biomarkers and
therapeutic targets.
5. Conclusion
Metabolomics provides a novel approach to identify alterations
in multiple biochemical networks over the course of AD. Applica-
tion of metabolomics allowed identiﬁcation of both expected and
non-expected changes in biochemical pathways related to AD pathology
in both animalmodels of AD and in human samples. These ﬁndings high-
light the translational strength of metabolomics since there is consider-
able parallel between mouse and human metabolism. Metabolomic
proﬁling allows establishing dynamic changes in metabolites that cor-
relatewith disease severity in CSF and plasma,where changes in plasma
accuratelymimic changes in CSF, making it attractive for the clinical ap-
plication. Since metabolic changes associated with AD progression
occur prior to the development of clinical symptoms, metabolomics
by itself or in conjunction with the additional currently available bio-
markers for AD diagnosis (CSF and plasma levels of Aβ, tau and p-tau
along with the advanced imaging techniques) could serve as an addi-
tional tool to increase the accuracy of diagnostic, to predict the disease
progression, and to monitor the efﬁcacy of therapeutic intervention.
However, very few studies to date included both test and sample valida-
tion. Therefore, future work will be critical for conﬁrming current ﬁnd-
ings in the larger cohorts of patients.
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